Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genelux Corp.
Headquarters: San Diego, CA, United States of America
Website: http://www.genelux.com
Year Founded: 2001
Status: Public
Industry Sector: HealthTechnology
CEO: Thomas D. Zindrick
Number Of Employees: 23
Enterprise Value: $321,582,185
PE Ratio: -3.75
Exchange/Ticker 1: NASDAQ:GNLX
Exchange/Ticker 2: N/A
Latest Market Cap: $123,646,800
BioCentury | Aug 28, 2023
Management Tracks
Kurt Graves takes top spot at i2o
Plus: Lourie Zak becomes CFO at Genelux, and updates from Delve Bio, Leo, and Synthetica
BioCentury | Jul 21, 2023
Management Tracks
Janssen vet Vratsanos joins Jnana as CMO
Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more
BioCentury | Nov 16, 2021
Data Byte
The oncolytic virus pipeline
At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Feb 29, 2016
Product Development
Infectious enthusiasm
How oncolytic viruses are coming of age in cancer immunotherapy combinations
Items per page:
1 - 10 of 21